Recent Data from KATHERINE and APHINITY in HER2+ Breast Cancer

Sacituzumab govitecan plus pembrolizumab reduced symptom burden and improved functioning across multiple domains in the KEYNOTE-D19 study.

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Policies aimed at improving health coverage and financial assistance may help improve treatment affordability to ensure more equitable survival.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

T-DXd showed a consistent duration of response advantage vs THP regardless of prior treatment and mutational status among HER2+ breast cancer subgroups.

Data from OptiTROP-Breast02 support sac-TMT as a new treatment option for those with hormone receptor–positive, HER2-negative breast cancer.